18 | September | 2021 | B.M. Pharmaceuticals

ESMO: In newly diagnosed stomach cancer, 2 Opdivo-Yervoy flops show immunotherapy alone might not be the answer

18th September 2021 Uncategorised 0

ESMO: In newly diagnosed stomach cancer, 2 Opdivo-Yervoy flops show immunotherapy alone might not be the answer aliu Sat, 09/18/2021 – 12:45 More: ESMO: In newly diagnosed stomach cancer, 2 Opdivo-Yervoy flops show immunotherapy alone might not be the answer

ESMO: Regeneron, Sanofi take another stab at lung cancer with Libtayo-chemo win. Should Merck worry?

18th September 2021 Uncategorised 0

ESMO: Regeneron, Sanofi take another stab at lung cancer with Libtayo-chemo win. Should Merck worry? aliu Sat, 09/18/2021 – 09:49 More: ESMO: Regeneron, Sanofi take another stab at lung cancer with Libtayo-chemo win. Should Merck worry? Source: fierce

ESMO: Merck touts Keytruda's breast cancer survival win as first-to-market Tecentriq leaves the ring

18th September 2021 Uncategorised 0

ESMO: Merck touts Keytruda’s breast cancer survival win as first-to-market Tecentriq leaves the ring aliu Sat, 09/18/2021 – 04:57 More: ESMO: Merck touts Keytruda's breast cancer survival win as first-to-market Tecentriq leaves the ring Source: fierce

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Archive for 18th September 2021

ESMO: In newly diagnosed stomach cancer, 2 Opdivo-Yervoy flops show immunotherapy alone might not be the answer

ESMO: Regeneron, Sanofi take another stab at lung cancer with Libtayo-chemo win. Should Merck worry?

ESMO: Merck touts Keytruda's breast cancer survival win as first-to-market Tecentriq leaves the ring

Categories

Lorem ipsum

FAQ’s

Our Clients

Management

Community

Archive

Calendar